Table 4.
Univariate analysis for survivals
| Variable | 5-year OS, % | p value | 5-year PFS, % | p value |
|---|---|---|---|---|
| Sex, male/female (n = 90) | 76.4/84.3 | 0.544 | 24.3/32.8 | 0.701 |
| Age, < 65/≥ 65 yr (n = 90) | 85.0/68.8 | 0.224 | 30.6/21.0 | 0.235 |
| Stage (Rai system)a (n = 90) | 0.001 | 0.038 | ||
| 0 | 100 | 26.0 | ||
| I | 75.5 | 17.8 | ||
| II | 73.3 | 64.8 | ||
| III | 66.1 | 21.4 | ||
| IV | 68.2 | 25.0 | ||
| Stage (Binet) (n = 90), % a | 0.006 | 0.239 | ||
| A | 88.0 | 27.3 | ||
| B | 72.9 | 53.3 | ||
| C | 62.2 | 20.0 | ||
| Constitutional symptom (+/–) (n = 89), % | 76.4/84.3 | 0.266 | 25.4/26.9 | 0.869 |
| Lymphadenopathya (+/–) (n = 84) | 68.5/86.9 | 0.029 | 24.2/36.3 | 0.127 |
| Splenomegaly a (+/–) (n = 83), % | 63.4/84.0 | 0.003 | 33.2/25.7 | 0.340 |
| Extranodal involmenta (+/–) (n = 90), % | 37.5/81.0 | 0.008 | 50.0/27.9 | 0.639 |
| WBC count a, < 100/≥ 100 × 103/μL (n = 90) | 83.9/28.6 | < 0.001 | 29.3/14.3 | 0.049 |
| Hemoglobin b, < 10/≥ 10 g/dL (n = 89) | 55.9/85.7 | 0.004 | 11.8/30.6 | 0.056 |
| Platelet b, < 80/80 to < 110/≥ 110 × 103/μL (n = 90) | 46.7/92.3/81.7 | 0.032 | 13.3/0/33.3 | 0.174 |
| Bone marrow neoplastic cells, < 80%/≥ 80% (n = 63) | 88.0/73.1 | 0.021 | 28.7/41.4 | 0.296 |
| LDH, < 500/≥ 500 IU/L (n = 70) | 84.3/34.3 | 0.003 | 28.8/0 | 0.016 |
| Cytogenetics (n = 75)a | 0.002 | 0.006 | ||
| IgH mutation | 100 | 50.0 | ||
| Normal karyotype/other chromosomes | 82.3 | 29.7 | ||
| Del(11q) or del(17) or CK | 26.7 | 0 | ||
| Immunophenotyping, % | ||||
| SmIg (n = 50) | 0.623 | 0.572 | ||
| Kappa (+) | 83.1 | 35.6 | ||
| Lambda (+) | 76.0 | 13.6 | ||
| Negative | 87.5 | 21.1 | ||
| CD5 (n = 37) | 0.856 | 0.018 | ||
| Bright | 100 | 0 | ||
| Intermediate | 88.4 | 21.6 | ||
| Dim/Negative | 82.5 | 29.3 | ||
| CD20 (n = 30) | 0.138 | 0.058 | ||
| Bright | 90.0 | 53.5 | ||
| Intermediate/dim/negative | 76.9 | 12.7 | ||
| Initial chemotherapy regimen (n = 90) | 0.255 | 0.007 | ||
| FCR or RF | 75.0 | 53.3 | ||
| FC | 75.6 | 46.6 | ||
| Chlorambucil | 85.1 | 23.0 | ||
| Fludarabine | 59.8 | 15.4 | ||
| Others | 88.9 | 12.5 | ||
| 1st line chemotherapy response (n = 87) | < 0.001 | < 0.001 | ||
| CR | 100 | 66.2 | ||
| PR | 83.3 | 26.9 | ||
| SD | 66.9 | 0 | ||
| PD | 37.5 | 0 |
OS, overall survival; PFS, progression-free survival; WBC, white blood cell; LDH, lactate dehydrogenase; IgH, immunoglobulin heavy locus; CK, complex karyotype; CD, cluster of differentiation; FCR, fludarabine, cyclophosphamide, and rituximab; RF, rituximab and fludarabine; FC, fludarabine and cyclophosphamide; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
a
At diagnosis.
b
At the initiation of first-line chemotherapy.